Mianserine-doxepine

From Psychiatrienet
Revision as of 15:08, 17 November 2009 by Mariska (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine
Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin

Switch medication from mianserine to doxepin.[2] [3]

Nietinrijdenbord.png Stop mianserine
  • Before day 1: gradually reduce dosage of mianserine to a maximum of 60 mg/ day.
  • Day 1: reduce a dosage of 60 mg/day to 30 mg/day.
Eenrichtingbord.png Start doxepin

No wash-out period is needed.

  • Day 1: simultaneously start administration of doxepin in a dosage of 25 mg/day.
  • Day 8: stop administration of mianserine and continue administration of doxepin only in a dosage of 50 mg/day. If necessary, increase dosage of doxepin.
  • Start low, go slow.


  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.